Quest: FDA okays lab method to increase COVID-19 molecular diagnostics capacity

Quest Diagnostics has announced that the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for a “new laboratory technique that speeds the process of extracting viral RNA from specimens and will enable the company to expand its daily capacity of COVID-19 molecular diagnostic tests on behalf of patients in the United States.”

Quest Diagnostics press release